Recent Progress in Alzheimer's and Parkinson's Diseases
eBook - PDF

Recent Progress in Alzheimer's and Parkinson's Diseases

  1. 422 pages
  2. English
  3. PDF
  4. Available on iOS & Android
eBook - PDF

Recent Progress in Alzheimer's and Parkinson's Diseases

Book details
Table of contents
Citations

About This Book

This book brings together the proceedings of Alzheimer's and Parkinson's Diseases: New Perspectives, the Sixth International Conference on Alzheimer's Disease and Parkinson's Disease, held recently in Seville, Spain, and discusses the latest developments in the basic science and therapy of Alzheimer's and Parkinson's diseases by leading specialists

Frequently asked questions

Simply head over to the account section in settings and click on “Cancel Subscription” - it’s as simple as that. After you cancel, your membership will stay active for the remainder of the time you’ve paid for. Learn more here.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Both plans give you full access to the library and all of Perlego’s features. The only differences are the price and subscription period: With the annual plan you’ll save around 30% compared to 12 months on the monthly plan.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes, you can access Recent Progress in Alzheimer's and Parkinson's Diseases by Israel Hanin, Ramon Cacabelos, Abraham Fisher in PDF and/or ePUB format, as well as other popular books in Médecine & Neurologie. We have over one million books available in our catalogue for you to explore.

Information

Publisher
CRC Press
Year
2005
ISBN
9780203028353
Edition
1
Topic
Médecine
Subtopic
Neurologie

Table of contents

  1. Front cover
  2. Contents
  3. List of contributors
  4. Preface
  5. Chapter 1. Mechanisms of degeneraton in Parkinson's disease
  6. Chapter 2. Underlying biochemcial and molecular mechanisms of dyskinesia
  7. Chapter 3. Molecular neuropathology of parkinsonism
  8. Chapter 4. Familial parkinsonian mutations affect the ability of catecholaminergic neurons to withstand proteasome inhibition
  9. Chapter 5. Acetylcholinesterase, cholinergic signaling and Parkinson's disease
  10. Chapter 6. Bone marrow stem cells: possible source for cell therapy in Parkinson's disease
  11. Chapter 7. Insulin-like growth factor I and intracellular signal transduction pathways in aging and dementia
  12. Chapter 8. The interrelationships between gait and cognitive function
  13. Chapter 9. Advances in gene transfer and pharmacological regulation of protein aggreagation in the treatment of Alzheimer's Parkinson's diseases
  14. Chapter 10. - and -Synucleins: two parent proteins that display similar anti-apoptotic phenotypes but distinct responses t 6-hydroxydopamine-induced toxicity
  15. Chapter 11. Functional genomics and pharmacogentics in Alzheimer's disease
  16. Chapter 12. The genetics of tau and neurodegenerative disease
  17. Chapter 13. Amyloid plaques and neurofibrillary tangles in a triple transgenic model qualitative similarities with human Alzheimer's neuropathology
  18. Chapter 14. Apolipprotein E and Alzheimer's diseae: what has a decade told us?
  19. Chapter 15. Comparison of the effects of apolipoprotein E4 on presynaptic and cytoskeletal plasticity following environmental stimulation
  20. Chapter 16.. Cholesterol and the A cascade: pathological implication of apolipoprotein E in Alzheimer's disease
  21. Chapter 17. Brain inflammation and psychogeriatric diseases
  22. Chapter 18. Neuroinflammatory mechanisms are invovled in the early steps of the pathological cascade in Alzheimer's disease
  23. Chapter 19. Vascular nitric oxide: a key molecule in Alzheimer's disease pathogenesis
  24. Chapter 20. Alzheimer pathology and endoplasmic reticulum stress
  25. Chapter 21. Molecular mechanism of amyloid -peptide-induced impairment of neurtrasmission and memory in relation to oxidative stress
  26. Chapter 22. Regulating factors for microglial activation: implication for Alzheimer's disease and brain damage
  27. Chapter 23. Cerebrospinal fluid phosphorylated tau protein at serine 199 is a useful diagnostic biomarker in Alzheimer's diseae and mild cognitive impairment
  28. Chapter 24. Stem cell strategies for Alzheimer's disease
  29. Chapter 25. Can mild cognitive impairment predict Alzheimer's disease?
  30. Chapter 26. Water quality and cholesterol-induced pathology: differential effects of the M-1 muscarinic receptor agonist AF 267B on accumulation of Alzheimer-like amyloid in rabbit brain
  31. Chapter 27. Lack of effect of certoparin in P301L mutant tau pathology
  32. Chapter 28. Heparin-derived oligosaccharides as potential therapeutic agents in senile dementia and stroke
  33. Chapter 29. Glycosaminoglycans and neuroprotection: effect on cholinergic neurodegeneration
  34. Chapter 30. Orchestration of the functional subsites in the acetylcholinesterase active center-contribution to catalytic perfection and high reactivity toward specific ligands
  35. Chapter 31. Altered glycosylation of acetylcholinestrase in the Alzheimer's disease brain: involvement of 7 nicotinic acetylcholine receptors
  36. Chapter 32. Cholinotropic alterations in individuals with mild cognitive impairment and Alzhiemer's disease
  37. Chapter 33. Pharmacological properties of TV 3326, a cholinesterase and brain selective monoamine oxidase inhibitor for the treatment of dementia co-morbt with depression
  38. Chapter 34. Physostigmine and its analog phenserine have different effects on Alzheimer amyloid- precursor protein
  39. Chapter 35. Translation and processing of amyloid precursos protein (APP) by an M1 muscarinic agonist and an acetylcholinesterase inhibitor: the role of APP mRNA 5' -untranslated region sequences
  40. Chapter 36. Modulation of Alzheimer's amyloidosis by statins: possible mechanisms of action
  41. Chapter 37. -Secretase-progress and questions
  42. Chapter 38. Tau phosphorylation and assembly in tauopathies
  43. Chapter 39. Alzheimer's disease: a true tauopathy fueled by amyloid precursor protein dysfunction
  44. Chapter 40. Neurofibrillary degeneration: a promising target for the treatment of Alzheimer's disease and other tauopathies
  45. Chapter 41. Neuropathology and tau
  46. Chapter 42. Conformational analysis of tau and tau aggregates by fluorescence spectroscopy
  47. Chapter 43. Transglutaminase-catalyzed cross-linking of tau in Alzheimer's disease and progressive supranuclear palsy
  48. Chapter 44. The impact of extracellular amyloid- (A ) peptides on cortical neurotransmitters and of intracellular A accumulation on protein expression
  49. Chapter 45. Activation of Wnt signaling protects from amyloid- -peptide neurotoxicity
  50. Chapter 46. Human prion diseases
  51. Index
  52. Back cover